PTAB Invalidates Second and Third AbbVie Patents on Humira Dosing, Following Coherus’ Challenges

The PTO invalidated two more AbbVie patents on dosing regimens for Humira after continuing challenges from Coherus, which plans to submit its biosimilar version of the blockbuster drug for FDA approval later this year.

Humira totaled 63 percent of AbbVie’s global net sales in 2016 — bringing in $16.1 billion, with $10.4 billion in the U.S.

Coherus argued that the biweekly doses were obvious to professionals trained in treating rheumatoid arthritis patients, following the publication of certain clinical trial results and scientific papers. — Conor Hale